Dr. Reddy's Laboratories (DRREDDY) — Announcement

📢 Key Event
FDA approval granted for rituximab biosimilar in the United States

Dr. Reddy's Laboratories announced that the U.S. FDA approved its rituximab biosimilar for the U.S. market, strengthening its global biosimilars portfolio and advancing its presence in the United States. The approval follows successful FDA inspection and leverages an exclusive commercialization partnership with Fresenius Kabi. The company highlighted its capabilities in complex biologics and long-standing commitment to biosimilars development.

📄 View Original Announcement (PDF)

📊 Stock Analysis — DRREDDY ✨ Ask AI About This

About Dr. Reddy's Laboratories Limited (DRREDDY)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,11,568.6 Cr P/E: 20.0 ROE: 16.6% ROCE: 19.7%

View full DRREDDY stock details →

📡 Get AI alerts when DRREDDY files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DRREDDY — Free

💡 Ask AI about this filing

"How will the Fresenius Kabi partnership impact U.S. revenue growth?" "What is the timeline for U.S. commercial launch of the rituximab biosimilar?" "How does this approval compare to competitors' biosimilar entries in the U.S. market?"

Ask AI Free →

📊 More DRREDDY filings

See all DRREDDY filings →

🔥 Also filed on 1 August 2026

PNCINFRA PNC Infratech Limited Announcement HMAAGRO HMA Agro Industries Limited Insider Trading NIITLTD NIIT Limited Announcement RVNL Rail Vikas Nigam Limited Annual Report RVNL Rail Vikas Nigam Limited Annual Report LATENTVIEW Latent View Analytics Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DRREDDY files new disclosures

Track DRREDDY filings, board meetings, and corporate actions. Free email alerts at 5 PM.